The easiest way to peek inside the inner workings of a brand-new biotech company? Check out its pipeline. For some early-stage companies, however, what would otherwise be a useful chart is better referred to as a “hypeline.”

It’s a tongue-in-cheek moniker for the overly braggadocious renderings and descriptions of the drug candidates and therapies a new company hopes to bring to market. A normal pipeline might include just one column for preclinical studies. A “hypeline,” in contrast, will include milestones above and beyond the three traditional phases of clinical trials. Others might conveniently forget to represent later-stage clinical trials, like Inozyme, or find creative ways to represent discovery work, like Mersana did.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy